DLL4: A Potential Drug Target and Biomarker (G54567)

Target Name: DLL4

NCBI ID: G54567

DLL4

DLL4: A Potential Drug Target and Biomarker

DLL4 (doublecortin) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the superfamily of cysteine-rich proteins, known as cysteine-rich protein (CRP) genes. DLL4 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and gastrointestinal diseases.

DLL4's Structure and Function

DLL4 is a 26 kDa protein that consists of 254 amino acid residues. It has a unique structure that includes a N-terminal cytoplasmic domain, a transmembrane region, and a C-terminal T-loop region. The cytoplasmic domain is composed of a variable region that includes a putative N-endopeptide and a putative C-endopeptide. The transmembrane region is composed of a variable region that includes a putative transmembrane N-endopeptide and a putative transmembrane C-endopeptide. The T-loop region is composed of a variable region that includes a putative T-loop N-endopeptide and a putative T-loop C-endopeptide.

DLL4 is involved in various cellular processes, including cell adhesion, migration, and invasion. It has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative disorders, and gastrointestinal diseases.

DLL4 as a Potential Drug Target

DLL4 has been identified as a potential drug target for various diseases due to its unique structure and function. One of the main reasons for its potential as a drug target is its involvement in cell adhesion and migration. DLL4 has been shown to play a role in the regulation of cell adhesion and has been shown to interact with various signaling pathways, including the TGF-β pathway.

DLL4 has also been shown to be involved in the regulation of cell migration. It has been shown to play a role in the regulation of cell migration and has been shown to interact with various signaling pathways, including the NF-kappa-B pathway.

In addition to its involvement in cell adhesion and migration, DLL4 has also been shown to play a role in the regulation of inflammation and has been shown to interact with various signaling pathways, including the NF-kappa-B pathway.

DLL4 as a Biomarker

DLL4 has also been identified as a potential biomarker for various diseases due to its unique structure and function. One of the main reasons for its potential as a biomarker is its involvement in the regulation of cancer cell growth and progression. DLL4 has been shown to play a role in the regulation of cancer cell growth and has been shown to interact with various signaling pathways, including the TGF-β pathway.

DLL4 has also been shown to play a role in the regulation of neurodegenerative disorders. It has been shown to interact with various signaling pathways, including theNF-kappa-B pathway, and has been shown to play a role in the development and progression of neurodegenerative disorders.

DLL4 has also been shown to play a role in the regulation of gastrointestinal diseases. It has been shown to play a role in the regulation of cell signaling pathways that are involved in inflammation and has been shown to interact with various signaling pathways, including the NF-kappa-B pathway.

Conclusion

In conclusion, DLL4 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and function make it an attractive target for drug development and research. Further research is needed to fully understand the role of DLL4 in

Protein Name: Delta Like Canonical Notch Ligand 4

Functions: Involved in the Notch signaling pathway as Notch ligand (PubMed:11134954). Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting (PubMed:20616313). Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types (By similarity). During spinal cord neurogenesis, inhibits V2a interneuron fate (PubMed:17728344)

The "DLL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DLL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets